Results 231 to 240 of about 983,526 (287)

Arthroscopic Capsular Plication Shows Low Failure Rates and Meaningful Functional Improvement in Multidirectional Shoulder Instability With and Without Hypermobile Ehlers‐Danlos Syndrome

open access: yesArthroscopy, Sports Medicine, and Rehabilitation, EarlyView.
Purpose To evaluate clinical outcomes and failure rates after arthroscopic capsular plication for multidirectional shoulder instability in patients with and without hypermobile Ehlers‐Danlos syndrome. Methods A retrospective case series with prospectively collected outcomes was conducted between 2015 and 2023 in patients undergoing arthroscopic ...
Chandler M. Catanzaro   +6 more
wiley   +1 more source

No Significant Difference in Cost or Outcomes at 1‐Year Minimum Follow‐Up After Arthroscopic Partial Meniscectomy Comparing 1.9 mm Distal Chip‐on‐Tip Needlescope Versus 4 mm Glass Rod Lens Arthroscope: Both Treatments Are Highly Cost‐Effective

open access: yesArthroscopy, Sports Medicine, and Rehabilitation, EarlyView.
Purpose To evaluate cost, outcomes, and incremental cost‐effectiveness of arthroscopic partial meniscectomy comparing visualization using a 1.9 mm distal chip‐on‐tip needlescope versus a standard 4 mm glass rod lens arthroscope. Methods We retrospectively reviewed prospectively collected data (from a larger randomized controlled trial) on patients ...
James H. Lubowitz, Chad Lavender
wiley   +1 more source

From Interferon Signature to the Clinical Landscape: Type I Interferonopathies

open access: yesArthritis &Rheumatology, EarlyView.
Objective TypeI interferonopathies are heterogeneous diseases driven by dysregulated type I interferon (IFN‐I) signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. The aim of this study was to characterize the clinical, immunologic, genetic, molecular profiles of patients with suspected ...
Ismail Yaz   +13 more
wiley   +1 more source

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety Up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

open access: yesArthritis &Rheumatology, EarlyView.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week, double‐blind, placebo‐controlled, phase 3 Program for Evaluation
Philip J. Mease   +20 more
wiley   +1 more source

Few rights, great threats, endless struggles: setbacks and resistance in the last decade of fights for legal abortion in Brazil. [PDF]

open access: yesSex Reprod Health Matters
Cardoso NM   +4 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy